Skip to main content



Local Cdiff information for Kansas

Kansas

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Kansas.



Local Cdiff information for Kansas

Kansas

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Kansas.

Providers

Regulation

C. diff Infections

C. diff Infections
Total Reported Cases: 627
Hospital Onset: 627
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 0.80
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: No
Data Publicly Available: No
Data Validated: Yes
Facility-specific Data Publicly Reported: No
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: Not available
STATUTE >

State Contact

Joseph M. Scaletta, MPH, RN, CIC
Director, KDHE Healthcare-associated Infections Program
Kansas Department of Health and Environment
Bureau of Surveillance and Epidemiology
1000 SW Jackson, Suite 210
Topeka, 66612
(785) 296-4090
(785) 291-3775
EMAIL JOSEPH M. SCALETTA, MPH, RN, CIC >

CLINICAL TRIALS

ROAR

Official Title: REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
Trial No. NCT05835219
Type: Observational
Recruitment: Recruiting
Sponsor: Ferring Pharmaceuticals
Contact: Global Clinical Compliance
833-548-1402
EMAIL
Gender: All
Age: 18 Years and older

FMT National Registry

Official Title: Fecal Microbiota Transplant National Registry
Trial No. NCT03325855
Type: Observational
Recruitment: Recruiting
Sponsor: American Gastroenterological Association
Contact: Sonya Serra, MSc
301-941-2616
EMAIL
Gender: All
Age: All ages

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.

To Understand the Safety and Effects of a C. Difficile Vaccine

Official Title: A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a Clostridioides Difficile Vaccine Administered in a 2-Dose Regimen With Novel Adjuvants in Healthy Adults
Trial No. NCT05805826
Type: Interventional
Recruitment: Recruiting
Sponsor: Pfizer
Contact: Pfizer CT.gov Call Center
EMAIL >
Gender: All
Age: 65 Years and older